Patents by Inventor Zohar Keren

Zohar Keren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID
    Publication number: 20240263150
    Abstract: A method of treating a disease or disorder associated with excessive uric acid levels is disclosed herein. The method comprises administering to the subject by i.v. infusion an amount of a recombinant homotetrameric uricase enzyme comprising four uricase polypeptides having the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptides are crosslinked by polyethylene glycol (PEG) bis-aldehyde having a molecular weight of 2-3.5 kDa.
    Type: Application
    Filed: February 1, 2024
    Publication date: August 8, 2024
    Applicant: Protalix Ltd.
    Inventors: Ilya RUDERFER, Yakir NATAF, Gil ARVATZ, Uri HANANIA, Tamar ARIEL, Shelly ROZEN, Yael HAYON, Zohar KEREN, Orit COHEN-BARAK
  • IMMUNOMODULATORY COMPOSTIONS AND USE THEREOF
    Publication number: 20240010706
    Abstract: Chimeric molecules comprising a fibrinogen-related domain (FRED) from human fibrinogen-like protein 2 (FGL2) are provided. Immunomodulatory pharmaceutical compositions comprising the chimeric molecules, as well as methods for reducing inflammation and treating autoimmune disease in a subject by administering the chimeric molecules or immunomodulatory pharmaceutical compositions are also provided.
    Type: Application
    Filed: March 31, 2021
    Publication date: January 11, 2024
    Inventors: Ilana MANDEL, Motti HAKIM, Zohar KEREN, Yair SAPIR, Avidor SHULMAN, Tehila BEN-MOSHE
  • METHODS OF ALTERING PERIPHERAL B CELL POPULATIONS AND USES THEREOF
    Publication number: 20110142857
    Abstract: A method of altering peripheral B cell populations in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of depleting peripheral B cells in the subject, and wherein the subject does not have a hematologic cancer or an autoimmune disease, thereby altering the peripheral B cell populations in the subject.
    Type: Application
    Filed: July 19, 2009
    Publication date: June 16, 2011
    Applicant: RAPPAPORT FAMILY INSTITUE FOR RESEACH IN THE MADICAL SCIENCES EFRON STREET
    Inventors: Doron Melamed, Zohar Keren